A European paediatric cancer mission: aspiration or reality?

Pamela R. Kearns; Gilles Vassal; Ruth Ladenstein; Martin Schrappe; Andrea Biondi; Patricia Blanc; Angelika Eggert; Anita Kienesberger; Olga Kozhaeva; Rob Pieters; Kjeld Schmiegelow

doi:10.1016/S1470-2045(19)30487-5

A European paediatric cancer mission: aspiration or reality?

Pamela R. Kearns, Gilles Vassal, Ruth Ladenstein, Martin Schrappe, Andrea Biondi, Patricia Blanc, Angelika Eggert, Anita Kienesberger, Olga Kozhaeva, Rob Pieters, Kjeld Schmiegelow

Group Pieters

Research output: Contribution to journal › Comment/debate

11 Citations (Scopus)

Original language	English
Pages (from-to)	1200-1202
Number of pages	3
Journal	The Lancet Oncology
Volume	20
Issue number	9
DOIs	https://doi.org/10.1016/S1470-2045(19)30487-5
Publication status	Published - Sept 2019

Access to Document

10.1016/S1470-2045(19)30487-5

Cite this

@article{aae82e02a1494c04bc4b5ea33f254f95,

title = "A European paediatric cancer mission: aspiration or reality?",

author = "Kearns, {Pamela R.} and Gilles Vassal and Ruth Ladenstein and Martin Schrappe and Andrea Biondi and Patricia Blanc and Angelika Eggert and Anita Kienesberger and Olga Kozhaeva and Rob Pieters and Kjeld Schmiegelow",

note = "Funding Information: PRK reports personal fees from Bristol-Myers Squibb (BMS), Genzyme, Janssen, and AbbVie (outside the submitted work), and is president of the Society of Paediatric Oncology Europe (SIOPE) and a board member of the European Innovative Therapeutics for Children with Cancers (ITCC) network and the ACCELERATE international multistakeholder platform. GV is a board member of SIOPE; president of the ITCC network; chair of the ACCELERATE international multistakeholder platform; and adviser (does not accept personal remuneration) in paediatric oncology drug development for AstraZeneca, Bayer, BMS, Celgene, Incyte, Ipsen, Lilly, Merck, Novartis, Pfizer, Roche/Genentech, Servier, Takeda, and Tesaro. RL is a board member of SIOPE. MS reports grants from Deutsche Krebshilfe, Bonn, Germany; reports personal fees from JazzPharma; reports personal fees, speaker's board, and support for research from Servier (outside the submitted work); and is a board member of SIOPE. AB is an advisory board member of Novartis, Celgene, Incyte, and BMS (outside the submitted work). AE is a member of a working group within the activities of the national (German) decade against cancer. AK reports a memorandum of understanding with SIOPE and PanCare. OK is employed by SIOPE. All other authors declare no competing interests. ",

year = "2019",

month = sep,

doi = "10.1016/S1470-2045(19)30487-5",

language = "English",

volume = "20",

pages = "1200--1202",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Elsevier Ltd.",

number = "9",

}

TY - JOUR

T1 - A European paediatric cancer mission

T2 - aspiration or reality?

AU - Kearns, Pamela R.

AU - Vassal, Gilles

AU - Ladenstein, Ruth

AU - Schrappe, Martin

AU - Biondi, Andrea

AU - Blanc, Patricia

AU - Eggert, Angelika

AU - Kienesberger, Anita

AU - Kozhaeva, Olga

AU - Pieters, Rob

AU - Schmiegelow, Kjeld

N1 - Funding Information: PRK reports personal fees from Bristol-Myers Squibb (BMS), Genzyme, Janssen, and AbbVie (outside the submitted work), and is president of the Society of Paediatric Oncology Europe (SIOPE) and a board member of the European Innovative Therapeutics for Children with Cancers (ITCC) network and the ACCELERATE international multistakeholder platform. GV is a board member of SIOPE; president of the ITCC network; chair of the ACCELERATE international multistakeholder platform; and adviser (does not accept personal remuneration) in paediatric oncology drug development for AstraZeneca, Bayer, BMS, Celgene, Incyte, Ipsen, Lilly, Merck, Novartis, Pfizer, Roche/Genentech, Servier, Takeda, and Tesaro. RL is a board member of SIOPE. MS reports grants from Deutsche Krebshilfe, Bonn, Germany; reports personal fees from JazzPharma; reports personal fees, speaker's board, and support for research from Servier (outside the submitted work); and is a board member of SIOPE. AB is an advisory board member of Novartis, Celgene, Incyte, and BMS (outside the submitted work). AE is a member of a working group within the activities of the national (German) decade against cancer. AK reports a memorandum of understanding with SIOPE and PanCare. OK is employed by SIOPE. All other authors declare no competing interests.

PY - 2019/9

Y1 - 2019/9

UR - http://www.scopus.com/inward/record.url?scp=85071539272&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(19)30487-5

DO - 10.1016/S1470-2045(19)30487-5

M3 - Comment/debate

C2 - 31486360

AN - SCOPUS:85071539272

SN - 1470-2045

VL - 20

SP - 1200

EP - 1202

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 9

ER -